Increased colonic bile acid exposure: A relevant factor for symptoms and treatment in IBS

Gut

Volumn 64, Issue 1, 2015, Pages 84-92

  Bajor, Antal ^a   Törnblom, Hans ^a   Rudling, Mats ^b   Ung, Kjell Arne ^c   Simrén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SKARABORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; FIBROBLAST GROWTH FACTOR; 23-SELENO-25-HOMOTAUROCHOLIC ACID; BILE ACID; TAUROCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE ACID SYNTHESIS; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; DEFECATION HABIT; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; EXPOSURE; FEMALE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; COLON; DIAGNOSTIC USE; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BILE ACIDS AND SALTS; COLON; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; TAUROCHOLIC ACID; YOUNG ADULT;

EID: 84919714351     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305965     Document Type: Article

References (66)

1. Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010; 7: 565-81.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21 e4.
3. Tornblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 2012; 107: 754-60.
4. Posserud I, Syrous A, Lindstrom L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23.
5. Larsson MH, Simren M, Thomas EA, et al. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 812-20.
6. Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007; 39: 201-15.
7. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
8. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005; 17: 311-16.
9. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 2002; 282:G443-9.
10. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971; 50: 1569-77.
11. Wingate DL, Phillips SF, Hofmann AF. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J Clin Invest 1973; 52: 1230-6.
12. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
13. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 645-64.
14. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978; 13: 408-16.
15. Taylor I, Basu P, Hammond P, et al. Effect of bile acid perfusion on colonic motor function in patients with the irritable colon syndrome. Gut 1980; 21: 843-7.
16. Wong BS, Camilleri M, Carlson PJ, et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222-6.
17. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58, 58 e1.
18. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15 e3.
19. Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009; 21: 734-e43.
20. Aldini R, Roda A, Festi D, et al. Bile acid malabsorption and bile acid diarrhea in intestinal resection. Dig Dis Sci 1982; 27: 495-502.
21. Jacobsen O, Hojgaard L, Hylander Moller E, et al. Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 1985; 290: 1315-8.
22. Borghede MK, Schlutter JM, Agnholt JS, et al. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur J Intern Med 2011; 22:e137-40.
23. Galatola G. The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: an uncontrolled open multicentre study. Eur J Gastroenterol Hepatol 1992; 4: 533-37.
24. Wildt S, Norby Rasmussen S, Lysgard Madsen J, et al. Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol 2003; 38: 826-30.
25. Fernandez-Banares F, Esteve M, Salas A, et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007; 102: 2520-8.
26. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Aliment Pharmacol Ther 2009; 30: 707-17.
27. Thaysen EH, Orholm M, Arnfred T, et al. Assessment of ileal function by abdominal counting of the retention of a gamma emitting bile acid analogue. Gut 1982; 23: 862-5.
28. Sciarretta G, Fagioli G, Furno A, et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 1987; 28: 970-5.
29. Vijayvargiya P, Camilleri M, Shin A, et al. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013; 11: 1232-9.
30. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 117-23.
31. Eusufzai S, Axelson M, Angelin B, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993; 34: 698-701.
32. Sauter GH, Munzing W, von Ritter C, et al. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci 1999; 44: 14-19.
33. Bajor A, Kilander A, Fae A, et al. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol 2006; 18: 397-403.
34. Bajor A, Kilander A, Sjovall H, et al. The bile acid turnover rate assessed with the (75)SeHCAT test is stable in chronic diarrhoea but slightly decreased in healthy subjects after a long period of time. Dig Dis Sci 2008; 53: 2935-40.
35. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 2008; 5: 42-8.
36. Chiang JY Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-66.
37. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(SUPPL. 2):II43-7.
38. Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580-8.
39. Ung KA, Kilander A, Nilsson O, et al. Long-term course in collagenous colitis and the impact of bile acid malabsorption and bile acid sequestrants on histopathology and clinical features. Scand J Gastroenterol 2001; 36: 601-9.
40. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol 2003; 38: 947-54.
41. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-40.
42. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
43. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-51.
44. Galman C, Arvidsson I, Angelin B, et al. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003; 44: 859-66.
45. Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 1445-53.
46. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
47. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003; 38: 36-42.
48. Sadik R, Abrahamsson H, Ung KA, et al. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004; 99: 711-18.
49. Sadik R, Bjornsson E, Simren M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010; 22: 102-8.
50. Sadik R, Stotzer PO, Simren M, et al. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 2008; 20: 197-205.
51. Smith MJ, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 2000; 34: 448-51.
52. Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538.
53. Muller M, Willen R, Stotzer PO. Colonoscopy and SeHCAT for investigation of chronic diarrhea. Digestion 2004; 69: 211-18.
54. Habba SF Diarrhea Predominant Irritable Bowel Syndrome (IBS-D): fact or fiction. Med Hypotheses 2011; 76: 97-9.
55. Gunnarsson J, Simren M. Efficient diagnosis of suspected functional bowel disorders. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 498-507.
56. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 1270-5 e1.
57. Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-e82.
58. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 513-20, e246-7.
59. Wong BS, Camilleri M, Carlson PJ, et al. A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-42.
60. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013; 22: 277-84.
61. Simren M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Aliment Pharmacol Ther 2011; 34: 41-50.
62. Camilleri M, Di Lorenzo C. Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr 2012; 54: 446-53.
63. Delgado-Aros S, Camilleri M, Garcia MA, et al. High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol 2008; 295:G382-8.
64. Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of Fibroblast Growth Factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304:G940-8.
65. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
66. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013; 38: 967-76.